WALTHAM, Mass., July 01, 2022--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ImmunoGen (IMGN) inks a collaboration deal with privately-held Oxford BioTherapeutics to develop novel antibody-drug conjugates by complementing each other's proprietary technologies.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...